Compare Cassava Sciences Inc (FLNA) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Global X Uranium ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Global X Uranium ETF is far larger — about 139.1× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 5,287,170). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Global X Uranium ETF for 62 Days on average.
| FLNA | URA | |
|---|---|---|
Market Cap | $39.40M | $5.48B |
Volume | 759,018 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $4.64 | $61.81 |
52-Week Low | $0.68 | $37.52 |
Typical Hold Time | 37 Days | 62 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
URA, the Global X Uranium ETF, trades at $38.56, down 3.43% in the last session amid a bearish technical signal. Key support lies at $37, with resistance at $39. The fund provides exposure to uranium miners and nuclear energy companies, benefiting from structural supply deficits and rising demand for reliable power, particularly from AI data centers. Recent index additions like Terra Innovatum and Eagle Nuclear Energy reflect ongoing sector expansion.
The outlook for URA is mixed; long-term demand drivers from nuclear energy adoption and AI power needs are strong, but near-term price volatility and concentrated holdings pose risks. Investors should weigh the sector's growth potential against ETF-specific fluctuations and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
